286 related articles for article (PubMed ID: 22131893)
21. Ulcerative colitis: conservative management and long-term effects.
Kühbacher T; Schreiber S; Fölsch UR
Langenbecks Arch Surg; 2004 Oct; 389(5):350-3. PubMed ID: 15133672
[TBL] [Abstract][Full Text] [Related]
22. Emerging Treatment Options in Mild to Moderate Ulcerative Colitis.
Lichtenstein GR; Hanauer SB; Sandborn WJ
Gastroenterol Hepatol (N Y); 2015 Mar; 11(3 Suppl 1):1-16. PubMed ID: 26491415
[TBL] [Abstract][Full Text] [Related]
23. Ulcerative Colitis.
Feuerstein JD; Moss AC; Farraye FA
Mayo Clin Proc; 2019 Jul; 94(7):1357-1373. PubMed ID: 31272578
[TBL] [Abstract][Full Text] [Related]
24. Long-term treatment of patients with a history of ulcerative colitis who develop gastritis and pan-enteritis after colectomy.
Hoentjen F; Hanauer SB; Hart J; Rubin DT
J Clin Gastroenterol; 2013 Jan; 47(1):52-7. PubMed ID: 22858512
[TBL] [Abstract][Full Text] [Related]
25. Inflammatory bowel disease: current therapeutic options.
Domènech E
Digestion; 2006; 73 Suppl 1():67-76. PubMed ID: 16498254
[TBL] [Abstract][Full Text] [Related]
26. Promising biological therapies for ulcerative colitis: A review of the literature.
Akiho H; Yokoyama A; Abe S; Nakazono Y; Murakami M; Otsuka Y; Fukawa K; Esaki M; Niina Y; Ogino H
World J Gastrointest Pathophysiol; 2015 Nov; 6(4):219-27. PubMed ID: 26600980
[TBL] [Abstract][Full Text] [Related]
27. Surgery in ulcerative colitis: When? How?
Gallo G; Kotze PG; Spinelli A
Best Pract Res Clin Gastroenterol; 2018; 32-33():71-78. PubMed ID: 30060941
[TBL] [Abstract][Full Text] [Related]
28. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus.
Bressler B; Marshall JK; Bernstein CN; Bitton A; Jones J; Leontiadis GI; Panaccione R; Steinhart AH; Tse F; Feagan B;
Gastroenterology; 2015 May; 148(5):1035-1058.e3. PubMed ID: 25747596
[TBL] [Abstract][Full Text] [Related]
29. [Management of diagnosis and treatment in ulcerative colitis].
Klotz C; Barret M; Dhooge M; Oudjit A; Chaussade S; Coriat R; Abitbol V
Presse Med; 2015 Feb; 44(2):144-9. PubMed ID: 25534469
[TBL] [Abstract][Full Text] [Related]
30. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.
Damião AOMC; de Azevedo MFC; Carlos AS; Wada MY; Silva TVM; Feitosa FC
World J Gastroenterol; 2019 Mar; 25(9):1142-1157. PubMed ID: 30863001
[TBL] [Abstract][Full Text] [Related]
31. Golimumab in unresponsive ulcerative colitis.
Lippert E; Müller M; Ott C
Biologics; 2014; 8():207-10. PubMed ID: 24904202
[TBL] [Abstract][Full Text] [Related]
32. Current treatment of ulcerative colitis.
Meier J; Sturm A
World J Gastroenterol; 2011 Jul; 17(27):3204-12. PubMed ID: 21912469
[TBL] [Abstract][Full Text] [Related]
33. [Medical therapy of inflammatory bowel diseases: ulcerative colitis].
Lakatos L; Lakatos PL
Orv Hetil; 2007 Jun; 148(25):1163-70. PubMed ID: 17573252
[TBL] [Abstract][Full Text] [Related]
34. Treatment of ulcerative colitis.
Blonski W; Buchner AM; Lichtenstein GR
Curr Opin Gastroenterol; 2014 Jan; 30(1):84-96. PubMed ID: 24285003
[TBL] [Abstract][Full Text] [Related]
35. Vedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn's disease.
Cherry LN; Yunker NS; Lambert ER; Vaughan D; Lowe DK
Ther Adv Chronic Dis; 2015 Sep; 6(5):224-33. PubMed ID: 26336591
[TBL] [Abstract][Full Text] [Related]
36. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
37. Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission.
Armuzzi A; Pugliese D; Danese S; Rizzo G; Felice C; Marzo M; Andrisani G; Fiorino G; Sociale O; Papa A; De Vitis I; Rapaccini GL; Guidi L
Inflamm Bowel Dis; 2013 Apr; 19(5):1065-72. PubMed ID: 23448790
[TBL] [Abstract][Full Text] [Related]
38. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
[TBL] [Abstract][Full Text] [Related]
39. Curcumin as a therapeutic agent for blocking NF-κB activation in ulcerative colitis.
Wang Y; Tang Q; Duan P; Yang L
Immunopharmacol Immunotoxicol; 2018 Dec; 40(6):476-482. PubMed ID: 30111198
[TBL] [Abstract][Full Text] [Related]
40. Drug therapy for ulcerative colitis.
Xu CT; Meng SY; Pan BR
World J Gastroenterol; 2004 Aug; 10(16):2311-7. PubMed ID: 15285010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
